Watch this webinar where we address one of the main challenges in bringing AAV-based therapies to patients, is the ability to efficiently translate bench-scale processes to commercial GMP manufacturing while meeting the high dosage requirements. Our Experts from Polyplus, Exothera and Alexion collaborated for the development of a highly scalable AAV manufacturing platform with a capacity ranging from 1L to 200L and 2000L.

Key Learning Objectives:

• Developing scalable transfection process with DOE (Design of Experiments)
• Scaling-up while maintaining consistent transfection complex growth for efficient delivery to cells